Skip to main content
    T

    Tourmaline Bio Inc. (TRML)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $47.98
    +0.00 (+0.00%)

    Market Cap: $1.23B

    Last updated: Nov 06, 2026 at 4:00 PM ET

    Tourmaline Bio Inc. (TRML) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2025. Financial statements from company filings, amounts in US dollars.

    Tourmaline Bio reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$73.21M, operating cash flow was -$77.26M and free cash flow was -$77.27M. The quarter ended Jun 30, 2025 had revenue of $0 and net income of -$23.09M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $89.73M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Jun 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$0$379.00K
    Gross profit$0$0$0$0$0-$379.00K
    Research and development$66.98M$32.37M$17.53M$34.24M$15.28M$13.37M
    Operating income-$89.73M-$45.41M-$19.70M-$47.51M-$22.68M-$18.38M
    Net income-$73.21M-$42.12M-$19.70M-$47.83M-$22.71M-$18.16M
    EBITDAN/AN/A-$19.70M-$46.46M-$22.14M-$17.78M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Revenue$0$0$40.00K$0$0$0$2.28M$0$0$0$0$0
    Gross profit$0$0$20.00K$0$0$0$1.14M$0$0$0-$553.00K$0
    Operating income-$25.97M-$26.23M-$25.81M-$24.44M-$21.97M-$17.52M-$14.89M-$6.64M-$16.37M-$7.50M$36.95M-$19.82M
    Net income-$23.09M-$22.97M-$22.23M-$20.18M-$17.49M-$13.31M-$12.90M-$5.59M-$16.13M-$7.50M$35.66M-$19.01M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $227.00K by $30.28M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$309.00M$210.29M$9.10M$251.42M$152.78M$41.94M
    Current assets$268.84M$208.87M$8.31M$246.51M$150.75M$40.79M
    Cash and equivalents$30.51M$140.73M$8.26M$18.61M$17.59M$38.98M
    Total liabilities$8.95M$5.25M$1.71M$8.61M$4.77M$2.35M
    Short-term debt$227.00K$221.00K$162.00K$150.00KN/AN/A
    Shareholder equity$300.05M$205.04M-$19.73M$242.81M-$38.15M$39.59M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022
    Total assets$269.30M$287.50M$309.00M$328.45M$344.79M$359.17M$210.29M$151.06M$159.12M$172.61M$9.10M$206.54M
    Total liabilities$10.10M$7.63M$8.95M$7.38M$6.51M$5.03M$5.25M$8.19M$10.69M$10.88M$28.83M$11.68M
    Cash and equivalents$31.42M$35.33M$30.51M$35.01M$70.15M$98.29M$140.73M$67.08M$18.35M$24.22M$8.26M$18.47M
    Shareholder equity$259.19M$279.86M$300.05M$321.07M$338.28M$354.14M$205.04M$142.87M$148.43M$161.73M-$19.73M$194.87M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$77.26M-$28.08M-$6.46M-$39.99M-$19.21M-$17.66M
    Capital expenditures$9.00K$56.00K$68.00K$2.44M$1.29M$562.00K
    Free cash flow-$77.27M-$28.14M-$6.53M-$42.42M-$20.50M-$18.22M
    Share repurchases$4.00K$0N/A$12.86B$526.00KN/A
    Investing cash flow-$194.31M$3.84M-$5.07M-$96.39M-$133.30M-$562.00K
    Financing cash flow$161.35M$156.72M$19.85M$137.40M$131.12M$36.20M
    Fiscal years ended Dec 2019 to Dec 2024

    Quarterly

    Line itemJun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$20.26M-$21.68M-$20.89M-$23.44M-$18.01M-$14.92M-$9.35M-$5.40M-$9.54M-$3.79M$40.53M
    Capital expenditures$7.00K$9.00K$9.00K$0$0$0$2.00K$17.00K$13.00K$24.00K$2.71M
    Free cash flow-$20.27M-$21.69M-$20.90M-$23.44M-$18.01M-$14.92M-$9.36M-$5.41M-$9.55M-$3.81M$37.82M
    Last 11 quarters

    Frequently Asked Questions About TRML

    What is Tourmaline Bio's annual revenue?

    Tourmaline Bio reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is Tourmaline Bio profitable?

    No. Tourmaline Bio reported net income of -$73.21M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does TRML generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$77.26M minus capital expenditures of $9.00K produced free cash flow of -$77.27M.

    How much debt does Tourmaline Bio have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $227.00K and cash and equivalents of $30.51M.